1-20 of 40
L Gianni
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

O Metzger, S Mandrekar, S Loibl, C Mundhenke, S Seiler, P Valagussa, E Lim, D Tripathy, EP Winer, C Huang, L Carey, P Francis, K Miller, MP Goetz, A Prat, S Loi, I Krop, L Gianni, S Delalogue, I Vaz-Luis, T Dockter, J Lanzillotti, E Ciruelos, AM DeMichele
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): OT3-02-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-OT3-02-07
Published: 15 February 2019
View article
Journal Articles

Abstract P1-10-06: A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for primary endocrine responsive breast cancer (TREND; IBCSG 41-13)

M Colleoni, K Gray, E Munzone, S Dellapasqua, C Zamagni, L Gianni, H Johansson, G Viale, R Kammler, R Maibach, M Rabaglio-Poretti, A Di Leo, AS Coates, RD Gelber, MM Regan, A Goldhirsch
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P1-10-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P1-10-06
Published: 15 February 2018
View article
Journal Articles

Abstract P3-11-05: Everolimus-exemestane (EE) vs palbociclib-fulvestrant (PF) or abemaciclib-fulvestrant (AF) or everolimus-fulvestrant (EF) in the treatment of metastatic HR+, HER2- metastatic breast cancer and prior aromatase inhibitors treatment. An indirect comparison with network meta-analysis

L Gianni, V Arcangeli, C Gianni, L Stocchi, L Menghini, D Samorani, C Ridolfi, T Emiliano, D Tassinari
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P3-11-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P3-11-05
Published: 15 February 2018
View article
Journal Articles

Abstract P1-13-06: Safety of trastuzumab in the subcutaneous formulation for the treatment of HER2 positive early breast cancer (eBC) patients: Primary results of SCHEARLY trial

M Zambetti, F Montemurro, P Morandi, C Zamagni, A Stell, A Rozzi, L Gianni
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P1-13-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P1-13-06
Published: 15 February 2018
View article
Journal Articles

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

I Krop, V Abramson, M Colleoni, T Traina, F Holmes, L Estevez, L Hart, A Awada, C Zamagni, P Morris, L Schwartzberg, S Chan, D Wheatley, A Gucalp, L Biganzoli, J Steinberg, L Gianni, M Trudeau, IC Tudor, D Markova, E Barry, J Tarazi, R Stewart, E Winer, DA Yardley
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): GS4-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-GS4-07
Published: 15 February 2018
View article
Journal Articles

Abstract P1-10-07: Efficacy and safety results from a randomized, phase II study of CC-486 in combination with fulvestrant in postmenopausal women with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer (MBC)

M Campone, J Sachdev, GV Bianchi, JT Beck, N Martínez-Jáñez, J Cortes, M Schmidt, C Zamagni, P Chen, J Miller, A Fandi, L Gianni
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P1-10-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P1-10-07
Published: 15 February 2018
View article
Journal Articles

Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

A Musolino, S Gori, L Cavanna, C Graiff, A Frassoldati, E Bria, G Bisagni, A Zambelli, G Partesotti, A Brandes, A Bonetti, L Moscetti, C Zamagni, A Rocca, D Generali, F Montemurro, L Gianni, M Tognetto, G Maglietta, R Todeschini
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): OT1-03-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-OT1-03-03
Published: 15 February 2018
View article
Journal Articles

Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer

O Metzger-Filho, S Mandrekar, S Loibl, E Ciruelos, L Gianni, E Lim, K Miller, C Huang, M Koehler, P Francis, P Valagussa, S Goel, A Prat, M Goetz, S Loi, I Krop, L Carey, J Lanzillotti, E Winer, D Tripathy, A DeMichele
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): OT3-05-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-OT3-05-07
Published: 15 February 2018
View article
Journal Articles

Abstract OT2-01-07: A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

H Rugo, S Tolaney, M Dickler, P Kabos, C-L Ho, H Wildiers, G Jerusalem, JE Alés-Martínez, A Hossain, E Johnston, L Gianni
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): OT2-01-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-OT2-01-07
Published: 15 February 2017
View article
Journal Articles

Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer

I Krop, J Cortes, K Miller, MT Huizing, L Provencher, L Gianni, S Chan, M Trudeau, J Steinberg, J Sugg, M Liosatos, VE Paton, A Peterson, A Wardley
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P4-22-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P4-22-08
Published: 15 February 2017
View article
Journal Articles

Abstract P4-21-39: Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study

L Gianni, G Bisagni, M Colleoni, L Del Mastro, C Zamagni, M Mansutti, M Zambetti, A Frassoldati, R De Fato, P Valagussa, G Viale
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P4-21-39.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P4-21-39
Published: 15 February 2017
View article
Journal Articles

Abstract PD6-04: HOHO study: How European and US young women cope with breast cancer and fertility concerns

O Pagani, V Bagnardi, M Ruggeri, N Bianco, E Gallerani, K Buser, M Giordano, L Gianni, M Rabaglio, A Freschi, E Cretella, M Clerico, D Amadori, E Simoncini, M Ciccarese, D Rauch, A Glaus, R Berardi, A Franzetti, KJ Ruddy, S Gelber, AH Partridge, M Colleoni
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): PD6-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-PD6-04
Published: 15 February 2017
View article
Journal Articles

Abstract P1-09-04: Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies

G Bianchini, T Pienkowski, Y-H Im, GV Bianchi, L-M Tseng, M-C Liu, A Lluch, J de la Haba-Rodríguez, V Semiglazov, D-Y Oh, B Poirier, JL Pedrini, P Valagussa, L Gianni
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P1-09-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P1-09-04
Published: 15 February 2017
View article
Journal Articles

Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

I Krop, V Abramson, M Colleoni, FA Holmes, L Estevez, L Hart, A Awada, C Zamagni, P Morris, L Schwartzberg, S Chan, D Wheatley, A Guculp, L Biganzoli, J Steinberg, L Gianni, M Trudeau, CM Kelly, H Uppal, IC Tudor, A Peterson, E Winer, DA Yardley
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P2-08-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P2-08-01
Published: 15 February 2017
View article
Journal Articles

Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis

C Jackisch, MJ Piccart, RD Gelber, M Procter, A Goldhirsch, E DeAzambuja, G Castro, Jr, M Untch, I Smith, L Gianni, J Baselga, N Al-Sakaff, S Lauer, E Mcfadden, B Leyland-Jones, R Bell, M Dowsett, D Cameron
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): PD5-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-PD5-01
Published: 15 February 2016
View article
Journal Articles

Abstract P4-04-04: Triple-negative (TN) and HER2+ breast cancers (BC) have different immune milieu in primary and metastatic tumors

G Bianchini, M Riba, S Zambelli, A Safonov, R Ogiya, T Jiang, C Hatzis, N Niikura, M Zambetti, T Iwamoto, L Pusztai, L Gianni
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): P4-04-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-P4-04-04
Published: 15 February 2016
View article
Journal Articles

Abstract P4-14-14: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

SM Swain, A Schneeweiss, L Gianni, A Stein, V McNally, S Heeson, C Portera, B Yoo, JC Cortes, J Baselga
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): P4-14-14.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-P4-14-14
Published: 15 February 2016
View article
Journal Articles

Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study

V Diéras, D Miles, S Verma, M Pegram, M Welslau, J Baselga, I Krop, K Blackwell, B Kang, J Xu, M Green, L Gianni
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): P4-14-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-P4-14-01
Published: 15 February 2016
View article
Journal Articles

Abstract OT3-2-01: A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer

DA Yardley, A Awada, J Cortes, HA Burris, A Peterson, S Bhattacharya, L Gianni, K Miller, E Winer
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): OT3-2-01.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-OT3-2-01
Published: 15 December 2013
View article
Journal Articles

Abstract P2-15-03: Cardiac safety of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (EBC): Final data from TDM4874g

IE Krop, TM Suter, L Dirix, G Romieu, C Zamagni, ML Citron, M Campone, CT Dang, N Xu, M Smitt, L Gianni
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): P2-15-03.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-P2-15-03
Published: 15 December 2013
View article